Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Autor: Ella, Raches, Reddy, Siddarth, Blackwelder, William, Potdar, Varsha, Yadav, Pragya, Sarangi, Vamshi, Aileni, Vinay K, Kanungo, Suman, Rai, Sanjay, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar, Mohapatra, Satyajit, Pandey, Anil, Ranganadin, Pajanivel, Gumashta, Raghavendra, Multani, Manish, Mohammad, Shameem, Bhatt, Parul, Kumari, Laxmi, Sapkal, Gajanan, Gupta, Nivedita, Abraham, Priya, Panda, Samiran, Prasad, Sai, Bhargava, Balram, Ella, Krishna, Vadrevu, Krishna Mohan, Aggarwal, P., Aglawe, V., Ali, A., Anand, N., Awad, N., Bafna, V., Balasubramaniyam, G., Bandkar, A., Basha, P., Bharge, V., Bhate, A., Bhate, S., Bhavani, V., Bhosale, R., Chalapathy, DV, Chaubal, C., Chaudhary, D., Chavan, A., Desai, P., Dhodi, D., Dutta, S., Garg, R., Garg, K., George, M., Goyal, P., Guleria, R., Gupta, S., Jain, M., Jain, M.K., Jindal, S., Kalra, M., Kant, S., Khosla, P., Kulkarni, P., Kumar, P., Kumar, Y., Majumdar, A., Meshram, P., Mishra, V., Mohanty, S., Nair, J., Pandey, S., Panigrahi, S.K., Patil, B., Patil, V., Rahate, P., Raj, V., Ramanand, S., Rami, K., Ramraj, B., Rane, S., Rao, E.V., Rao, N., Raphael, R., Reddy, G., Redkar, V., Redkar, S., Sachdeva, A., Saha, J., Sahoo, J., Sampath, P., Savith, A., Shah, M., Shanmugam, L., Sharma, R., Sharma, P., Sharma, D., Singh, A., Singh, J., Singh, P., Sivaprakasam, S., Subramaniam, S., Sudheer, D., Tandon, S., Tariq, M., Tripathi, V., Vable, M., Verma, R., Waghmare, S.
Zdroj: The Lancet; December 2021, Vol. 398 Issue: 10317 p2173-2184, 12p
Abstrakt: We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.
Databáze: Supplemental Index